Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 11Recruiting 8Not yet recruiting 5Terminated 4Active not recruiting 4Unknown 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 629Prostatic Neoplasms 372Neoplasms 304Carcinoma, Non-Small-Cell Lung 216Lung Neoplasms 205Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 135Leukemia, Myeloid, Acute 129Neoplasm Metastasis 124Melanoma 116Brain Neoplasms 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 81Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66

Interventions

cabozantinib 2pembrolizumab 1lenvatinib 1Selenomethionine 1Nivolumab 1Ipilimumab 1Everolimus 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Clear-cell metastatic renal cell carcinoma × Clear all
NCT04388852 2026-05-20

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
65 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Prostatic Neoplasms

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
31 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05363631 2025-12-10

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

University of Iowa

Phase 1/2 Active not recruiting
55 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡